Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Creation of a Biological Collection of BRonchiaI and Pulmonary Tissues From Surgical wastE

NCT07780630 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-09-01
Last updated
2026-08-21

Condition(s) studied

COPD (Chronic Obstructive Pulmonary Disease)Asthma (Diagnosis)Safe Volunteers

Investigational drug(s) / intervention(s)

Fiberscopic samplesSputumNasal brushingblood sampling

Fiberscopic samples: Perform brushing and/or bronchial biopsies and/or BAL and/or aspiration during bronchial fiberscopy and surgical waste during a lobectomy.

Sputum: Sputum has been collected for biological analysis.

Nasal brushing: Nasal brushing is a minimally invasive medical procedure used to collect cellular samples from the nasal lining by gently rubbing a small cytology brush against the mucosa.

blood sampling: Blood sampling is the safe collection of a blood specimen from a vein, finger, or artery to run medical lab tests

Study summary

The biological samples and associated data will facilitate the successful implementation of the research collaboration between Bordeaux University Hospital and the University of Bordeaux on the pathophysiology of bronchopulmonary diseases. In the longer term, this research could lead to the discovery of new therapeutic targets for asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and acute respiratory distress syndrome.

Eligibility

Sex
ALL
Min age
1 Year
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female * Adult or children * Having required or necessitating, in the context of care or research involving the human person promoted by the Bordeaux University Hospital (ARISE, BIRDIES, ICEBERG, VIRCHILLD) or by Inserm (COBRA), either thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of the Haut Lévêque Hospital, or bronchial fiberscopy with biopsies and/or bronchial brushing and/or BAL at the children's hospital of the Pellegrin Hospital or at the Haut Lévêque Hospital. * Having received or, for children whose holders of parental authority have received, an information note with the possibility of opposition in accordance with the MR004 (French law - Commission Nationale de l'Informatique et des Libertés (CNIL)) Exclusion Criteria: * Patient or holder of parental authority for children who have expressed their opposition to participation in the research

Primary outcome measure(s)

  • Describe tobacco consumption — At enrollment
    Number pack in years
  • Describe tobacco statut — At enrollment
    Described as either non-smokers, former smokers or current smokers
  • Description of demographic status — At enrollment
    Gender (male or female)
  • Description of demographic status — At enrollment
    Age as years
  • Description of demographic status — At enrollment
    Body Mass Index (BMI) (kg/m\^2)
  • Mesure of lung function parameters — At enrollment
    FEV1: forced expiratory volume in 1 sec
  • Mesure of lung function parameters — At enrollment
    FVC: forced vital capacity
  • Mesure of lung function parameters — At enrollment
    FEF25-75: forced expiratory flow between 25 and 75% of the FVC
  • Mesure of lung function parameters — At enrollment
    TLC: total lung capacity
  • Mesure of lung function parameters — At enrollment
    RV: residual volume
  • Describe of disease status — At enrollment
    Described as Healthy, COPD or Asthma
  • Collection type — At enrollment
    Described as bronchial or lung specimens (frozen of embedded in paraffin), bronchial smooth muscle cells, bronchial epithelial cells, alveolar cells, arterial smooth muscle cells, arterial endothelial cells, fibrocytes, mesenchymal cells, lymphocytes, neutrophils, macrophages, organoïds.

Trial sites (1)

FacilityCityRegionStatus
CHU de Bordeaux Pessac France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07780630 on ClinicalTrials.gov ↗ ← All trials in France